Correlative Analysis of Overall Survival by Intrinsic Subtype Across the MONALEESA-2, -3, and -7 Studies of Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer

Lisa A. Carey,1 Nadia Solovieff,2 Fabrice André,3 Joyce O’Shaughnessy,4 David A. Cameron,5 Wolfgang Janni,6 Gabe S. Sonke,7 Yoon-Sim Yap,8 Denise A. Yardley,9 Juan Pablo Zarate,10 Tetiana Taran,11 Faye Su,10 Agnes Lteif,10 Aleix Prat12

1University of North Carolina, Chapel Hill, NC; 2Novartis Institutes for Biomedical Research, Cambridge, MA; 3Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; 4Texas Oncology-Baylor University Medical Center and The US Oncology Research Network, Dallas, TX; 5Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK; 6Department of Gynecology, University of Ulm, Ulm, Germany; 7Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; 8National Cancer Center Singapore, Singapore; 9Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN; 10Novartis Pharmaceuticals Corporation, East Hanover, NJ; 11Novartis Pharma AG, Basel, Switzerland; 12Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
Disclosure Information

Lisa Carey

- Institutional research funding from Syndax, Novartis, NanoString Technologies, AbbVie, Seattle Genetics, and Veracyte
- An immediate family member has a royalty-sharing agreement and investorship interest in licensed IP to start-up company Falcon Therapeutics
- Uncompensated relationships with Sanofi, Novartis, G1 Therapeutics, Genentech/Roche, GlaxoSmithKline, AstraZeneca/Daiichi Sankyo, Aptitude Health, Exact Sciences, and Eisai
**Introduction**

- Ribociclib + ET demonstrated statistically significant PFS and OS benefit in 3 phase 3 clinical trials (MONALEESA-2, -3, and -7) in patients with HR+/HER2− advanced breast cancer\(^1\)-\(^6\)

- A prior pooled analysis of patients in the MONALEESA trials demonstrated a significant PFS benefit with ribociclib + ET vs placebo + ET in the luminal A (HR, 0.63; \(P = .0007\)), luminal B (HR, 0.52; \(P < .0001\)), and HER2E (HR, 0.39; \(P < .0001\)) subtypes\(^7\)
  - Note the meta-analysis of PFS by intrinsic subtype in HR+ MBC (Schettini F, et al. SABCS 2021. Poster P4-07-08.)

- This retrospective exploratory analysis evaluated the association of intrinsic subtype with OS using tumor samples pooled from the MONALEESA-2, -3, and -7 trials

---

ET, endocrine therapy; HER2−, human epidermal growth factor receptor 2 negative; HER2E, human epidermal growth factor receptor 2 enriched; HR+, hormone receptor positive; MBC, metastatic breast cancer; OS, overall survival; PFS, progression-free survival.


---

This presentation is the intellectual property of the author/presenter. Contact them at lisa_carey@med.unc.edu for permission to reprint and/or distribute.
Methods

- Gene expression profiling was performed on tumor samples (primary and metastatic) by using a customized NanoString nCounter GX 800-gene panel, including 36/50 PAM50 genes
  - Intrinsic subtyping was performed using a 152-gene set that was selected based on the ability to identify PAM50 subtype in 48 independent tumors and the original PAM50 microarray training data set
- The relationships between PAM50-based subtypes with OS were evaluated using univariable and multivariable Cox proportional hazard models
  - Kaplan-Meier curves were generated, and median OS (95% CI) was estimated by subtype and treatment arm
  - Multivariable models were adjusted for known clinical prognostic factors
- The $P$ values generated are descriptive and were not adjusted for multiplicity or false discovery

OS, overall survival; PAM50, Prediction Analysis of Microarray 50.
Tumor samples and subtype distribution

Samples in this analysis (N = 997)\(^a\)

- Ribociclib + ET (n = 585) and placebo + ET (n = 412)
  - MONALEESA-2: 318 samples
  - MONALEESA-3: 414 samples
  - MONALEESA-7: 265 samples
- 71% were from primary tumors in the pooled data set
  - MONALEESA-2: 73% primary
  - MONALEESA-3: 68% primary
  - MONALEESA-7: 74% primary

---

\(^a\) Samples with normal-like subtype (n = 163) were excluded from this analysis because this subtype has a high proportion of normal tissue.
Consistent OS benefit in the ITT and biomarker populations

**ITT**
(N = 2066)

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Events, n</th>
<th>OS, median, mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo + ET</td>
<td>913</td>
<td>528</td>
<td>48.5</td>
</tr>
<tr>
<td>Ribociclib + ET</td>
<td>1153</td>
<td>544</td>
<td>58.8</td>
</tr>
</tbody>
</table>

HR = 0.76 (0.67-0.86)

*(P < .0001)*

**Biomarker**
(n = 997)

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Events, n</th>
<th>OS, median, mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo + ET</td>
<td>412</td>
<td>251</td>
<td>46.8</td>
</tr>
<tr>
<td>Ribociclib + ET</td>
<td>585</td>
<td>283</td>
<td>58.8</td>
</tr>
</tbody>
</table>

HR = 0.75 (0.63-0.89)

*(P = .0012)*

- Similar OS benefit with ribociclib + ET vs placebo + ET in both ITT and biomarker populations

ET, endocrine therapy; ITT, intent to treat; OS, overall survival.
Intrinsic subtype was prognostic for OS

**Placebo + ET**

<table>
<thead>
<tr>
<th>Subtype</th>
<th>n (%)</th>
<th>Events, n</th>
<th>OS, median, mo</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luminal A</td>
<td>222 (54)</td>
<td>122</td>
<td>54.6</td>
<td>48.3-66.2</td>
</tr>
<tr>
<td>Luminal B</td>
<td>124 (30)</td>
<td>79</td>
<td>44.9</td>
<td>35.5-52.6</td>
</tr>
<tr>
<td>HER2E</td>
<td>52 (13)</td>
<td>39</td>
<td>29.4</td>
<td>23.9-42.0</td>
</tr>
<tr>
<td>Basal-like</td>
<td>14 (3)</td>
<td>11</td>
<td>21.2</td>
<td>12.8-NR</td>
</tr>
</tbody>
</table>

**Ribociclib + ET**

<table>
<thead>
<tr>
<th>Subtype</th>
<th>n (%)</th>
<th>Events, n</th>
<th>OS, median, mo</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luminal A</td>
<td>322 (55)</td>
<td>135</td>
<td>68.0</td>
<td>61.5-69.2</td>
</tr>
<tr>
<td>Luminal B</td>
<td>154 (26)</td>
<td>75</td>
<td>58.8</td>
<td>48.3-69.2</td>
</tr>
<tr>
<td>HER2E</td>
<td>95 (16)</td>
<td>59</td>
<td>40.3</td>
<td>33.4-49.0</td>
</tr>
<tr>
<td>Basal-like</td>
<td>16 (3)</td>
<td>14</td>
<td>19.4</td>
<td>10.7-33.2</td>
</tr>
</tbody>
</table>

- OS was associated with subtype in both the ribociclib + ET and placebo + ET arms ($P < .0001$ for both)
- Median OS was longest in patients with luminal A tumors and shortest in those with basal-like tumors
Intrinsic subtype was prognostic for OS in multivariable models

<table>
<thead>
<tr>
<th></th>
<th>Ribociclib + ET</th>
<th>Placebo + ET</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjusted HR&lt;sup&gt;a&lt;/sup&gt;</td>
<td>95% CI</td>
</tr>
<tr>
<td>Luminal A</td>
<td>1.00</td>
<td>–</td>
</tr>
<tr>
<td>Luminal B</td>
<td>1.16</td>
<td>0.86-1.57</td>
</tr>
<tr>
<td>HER2E</td>
<td>1.83</td>
<td>1.33-2.52</td>
</tr>
<tr>
<td>Basal-like</td>
<td>7.06</td>
<td>3.73-13.40</td>
</tr>
</tbody>
</table>

Subtype remained prognostic for OS in both arms (P < .001 for both) after adjusting for clinical covariates

ECOG, Eastern Cooperative Oncology Group; ET, endocrine therapy; HR, hazard ratio; OS, overall survival.

<sup>a</sup> Obtained from multivariable Cox model, including age, prior chemotherapy, prior ET, ECOG performance status, visceral disease (presence of liver/lung metastases), bone-only metastases, histological grade, number of metastatic sites, tumor type, and de novo metastatic disease.
Consistent OS benefit observed with ribociclib in luminal A, luminal B, and HER2E subtypes in univariable analysis

- In univariable analysis, OS benefit with ribociclib + ET was observed in patients with luminal A, luminal B, and HER2E subtypes
  - Patients with basal-like subtype did not demonstrate OS benefit with ribociclib + ET, but the sample size was small (n = 30 total; 3% in each arm)
- Interaction test result between subtype and treatment arm was statistically significant ($P = .016$)
  - With basal-like subtype removed, the interaction test result was no longer statistically significant ($P = .47$)

ET, endocrine therapy; HER2E, human epidermal growth factor receptor 2 enriched; HR, hazard ratio; OS, overall survival.
## OS benefit observed with ribociclib in luminal A, luminal B, and HER2E subtypes in multivariable models

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Adjusted HR&lt;sup&gt;a&lt;/sup&gt;</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luminal A</td>
<td>0.77</td>
<td>0.60-0.99</td>
</tr>
<tr>
<td>Luminal B</td>
<td>0.63</td>
<td>0.46-0.88</td>
</tr>
<tr>
<td>HER2E</td>
<td>0.53</td>
<td>0.35-0.80</td>
</tr>
<tr>
<td>Basal-like</td>
<td>2.71</td>
<td>1.18-6.24</td>
</tr>
</tbody>
</table>

- Interaction test result between subtype and treatment arm remained statistically significant after adjusting for clinical covariates ($P = .0065$)
  - After removing basal-like subtype from this analysis, the interaction test result was no longer statistically significant ($P = .32$)

HER2E, human epidermal growth factor receptor 2 enriched; HR, hazard ratio; OS, overall survival.

<sup>a</sup> Obtained from multivariable Cox model, including age, prior chemotherapy, prior ET, ECOG performance status, visceral disease (presence of liver/lung metastases), bone-only metastases, histological grade, number of metastatic sites, tumor type, and de novo metastatic disease.
Conclusions

- In this pooled analysis of the MONALEESA-2, -3, and -7 trials, consistent OS benefit was observed with ribociclib + ET in the luminal A, luminal B, and HER2E subtypes
  - Patients with basal-like subtype (3% in each arm) did not derive benefit from ribociclib; however, these results should be interpreted with caution due to the small sample sizes in this subgroup
- The prognostic value of PAM50-based intrinsic subtype for OS in patients treated with ribociclib + ET and those treated with ET alone was confirmed
- The results of this analysis are consistent with those of the prior analysis of PFS using the pooled MONALEESA data set
- The activity of ribociclib + ET in the HER2E subtype, which has poor outcomes compared with luminal subtypes, is being further investigated in the phase 3 HARMONIA trial
  - HARMONIA will examine if ribociclib has a particular impact in HER2E tumors based on these clinical data and preclinical data generated in patient-derived xenograft models
- A genomic profiling analysis by intrinsic subtype across the MONALEESA trials is also being presented at SABCS 2021 (Prat A, et al. SABCS 2021. Spotlight Poster Discussion PD2-05)

ET, endocrine therapy; HER2E, human epidermal growth factor receptor 2 enriched; OS, overall survival.

a The phase 3 HARMONIA trial will evaluate patients with HER2E HR+/HER2– advanced breast cancer treated with ribociclib plus ET or palbociclib plus ET.
Acknowledgments

We thank the patients enrolled in these studies and their families as well as the study investigators.

We also thank the team that supported these trials.

Medical editorial assistance was provided by MediTech Media, Ltd, and was funded by Novartis Pharmaceuticals Corporation. The authors had final responsibility for the presentation.

Ribociclib was discovered by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals.
Scan the QR code below for copies of this presentation and a plain language summary

Copies of this presentation obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from SABCS® and the author of this presentation.